U.S. Markets close in 3 hrs 11 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
273.05+1.80 (+0.66%)
As of 12:49PM EDT. Market open.
People also watch
Full screen
Previous Close271.25
Bid272.24 x 200
Ask272.46 x 200
Day's Range269.09 - 273.53
52 Week Range232.00 - 333.65
Avg. Volume1,619,750
Market Cap58.33B
PE Ratio (TTM)17.10
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals5 hours ago

    Like Biogen, this Fidelity-backed startup is targeting a deadly infant disease

    Since being launched in 2014 with financing from Fidelity and other prominent investors, Cambridge-based Scholar Rock has been developing a drug that is designed to block a protein that limits muscle growth. On Wednesday, the privately-held, 40-employee company revealed for the first time which disease it plans to target: spinal muscular atrophy, or SMA, a leading genetic cause of death in infants. There was no approved treatment for SMA until December 2016, when the FDA green-lighted Biogen's (BIIB) Spinraza.

  • 2 Pharma Buyout Targets That May Surprise You
    Motley Foolyesterday

    2 Pharma Buyout Targets That May Surprise You

    When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here's why.

  • Benzinga5 days ago

    Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold

    Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...